ACS and Hyperlipidemia

Return to all Family Medicine Board Review sessions.

Estimated time to complete session: 60 min.

Learning Objectives

1. Identify the primary target for cholesterol lowering therapy based upon the Adult Treatment Panel III report.
2. Categorize risk stratification for cholesterol therapy based upon LDL-C risk factors and the Framingham Data.
3. Recognize the importance of hyperlipidemia therapy in the Metabolic Syndrome.
4. Recognize the hyperlipidemia therapy of coronary artery equivalent patients.
5. Relate the importance and role of intensive LDL cholesterol lowering therapy.

Additional Information

Technical Requirements: 

View technical requirements (opens in a new window).

CME Credit Information: 

View CME credit information (opens in a new window).

AAFP Staff: 

View AAFP staff list (opens in a new window).


View disclosures and disclaimers (opens in a new window).

Course summary
Available credit: 
  • 1.00 AAFP prescribed
Course opens: 
Course expires: 
Parent activity set: 

Jonathon Firnhaber, MD, FAAFP, Assistant Professor,  Residency Director, Department of Family Medicine, Brody School of Medicine at East Carolina University, Greenville, North Carolina

Available Credit

  • 1.00 AAFP prescribed

Accreditation Period

Course opens: 
Course expires: 
Please login or register to take this course.